The Investigational New Drug Application (IND) to Conduct FDA-regulated Clinical Trials
• Specify the role of an IND and the contexts in which it is required.
• Access key regulatory documents relating to INDs.
• Describe the contents and format of an IND submission.
• Describe the process of FDA review of an IND, the possible outcomes and sponsor’s responses.
• Identify actions necessary to maintain an active IND.
• Specify options for expanded-access use of investigational drugs.
An Investigational New Drug Application (IND) is a submission to the US Food and Drug Administration (FDA) for permission to conduct a clinical trial of a medicinal product. This module describes regulatory requirements that sponsors or sponsor-investigators must meet for successful compilation, filing and maintenance of INDs. The IND and its role are defined, and the contexts in which it is required are specified.
The information that must be included and the format in which it needs to be presented are outlined. The process of review by the FDA is described, and the outcomes and sponsor’s responses are discussed. The actions necessary to maintain an open IND are set out.
Finally, the regulatory provisions for expanded-access use of investigational drugs are described.
Module overview - An outline of the module’s scope and objectives, and notes on terminology.
Introduction to Investigational New Drug Applications (INDs) - This session explains the role and legal status of an IND, sets out the contexts in which one must be filed, summarises the responsibilities of sponsors and investigators, and outlines the pre-submission process.
IND content and format requirements - This session sets out IND contents required by regulations and describes how these are incorporated in a CTD-formatted submission. The significance of the FDA forms 1571 and 1572 are discussed. The major components of an application are outlined: general investiga- tional plan, investigator’s brochure, clinical protocol, Quality/CMC information, nonclinical data, and clinical information.
Filing and FDA review - Options and requirements for submission of an IND are set out, and the review procedure and its outcomes are described. The roles of FDA reviewers are outlined. The significance of a clinical hold and the sponsor’s response to a hold are discussed.
Maintenance of an IND - This session identifies the various types of IND amendments and reports: protocol amend- ments, IND safety reports, annual reports, and information amendments. It explains when they need to be made and outlines the regulations that govern them. The responsibili- ties of sponsors and investigators to report safety findings are described, as are require- ments for financial disclosure and record retention.
Expanded access use - This session describes the various types of expanded-access use of investigational drugs to treat patients outside of clinical trials and sketches a scenario of emergency use.
• Regulatory affairs professionals and other staff of pharmaceutical or biotechnology companies involved in clinical development of medicinal products; and
• Healthcare professionals conducting clinical research as sponsor-investigators or who wish to treat patients under an expanded-access scheme.
Our online training offers a wide range of benefits for professionals seeking to enhance their knowledge and expertise.
- World-Class Training
Learn from TÜV SÜD’s industry experts and training specialists.
- Flexible Learning Style
Study in your own time, at your own pace
- Continuous Feedback
Get prompt feedback from content-embedded assessment.
- Professional Certification
Get a globally recognized certificate and enhance your career development.
System requirements
- Chrome
- Safari
- Internet Explorer
- Firefox
- A high-speed internet connection will provide best results.
- An email address is required to register for courses.
- Microsoft Media Player or equivalent is needed to play audio and video files.
- Flash Player is used for content and interactive learning. If necessary, download and install Flash Player to ensure proper operation of course content.
1. What is included with the course?
Each course will include access to e-learning content, quizzes, and proof of completion. Additional resources may also be included and this will vary by course.
2. Can I pause the course and log in to it anytime?
Certainly. The course allows the learner to take a break and return to it within the defined access period (typically 365 days).
3. Are there any quizzes in the middle of the course?
Our e-learning courses are designed to promote interaction between learner and content and often include quizzes. Quizzes are designed to help understand where successful learning has been achieved, and where opportunities for additional review exist.
4. Can I get a refund if I cancel my enrollment?
Refunds cannot be provided once a course is activated. Please be sure to review course information prior to activation.
5. What happens if I don’t finish the course within the access period?
The standard access period is 365 days to allow sufficient time to complete your course.